Biopharma investors were recently wowed by data from a pipeline drug from Provention Bio which could delay the onset of type 1 diabetes in at-risk patients – and now UK biotech Tiziana is promoting its own contender in the field.
The share price of Provention Bio doubled last month after it released data which showed its immunotherapy PRV-031 (teplizumab) could delay the onset of of type 1 diabetes in children and adults by a median of two years. Teplizumab is a mouse derived anti-CD3 mAb, and is administered intravenously. It is being evaluated in the treatment of a range of autoimmune diseases, including type 1 diabetes among others.
The rise in share price followed a study published in The New England Journal of Medicine, which contained results from Provention’s phase 2 trial in 76 patients at risk of developing Type 1 diabetes (T1D)who were given teplizumab. These results showed a significant delay in the onset and diagnosis of Type 1 diabetes when compared to placebo, by a median of 2 years in high-risk children and adults. The results were even more impressive for a subgroup of patients, around 60%, who did not develop the condition at all in the study period.
Read On –> PMLive.com